SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern […]
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. […]
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the […]
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to […]
MaaT Pharma, a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization […]
Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University. […]
In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be […]
Quay Pharma, the leading pharmaceutical contract development and manufacturing organisation (CDMO), has been acquired by SGS, the Swiss-based world leading (TIC) Testing, Inspection and Certification company. The deal will provide Quay with the investment to […]
Microbiome-focused oncology drug company everImmune, a spin-out from France’s top cancer research center, has signed an agreement with contract development and manufacturing organization (CDMO) Biose Industrie to manufacture the drug substance and finished drug product […]
Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]
Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, […]